0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Invited Commentary

Hiram C. Polk Jr, MD; William G. Cheadle, MD
Arch Surg. 1994;129(10):1042. doi:10.1001/archsurg.1994.01420340056009.
Text Size: A A A
Published online

The pursuit of an effective immune adjuvant or restorative therapy designed to decrease the risk of infection or death from sepsis has been a continued focus of basic and clinical research for the last 15 years. This has now progressed to specific interleukins, cytokines, and mediators, as well as their respective antagonists, all of which amplify the inflammatory response. The fundamental concept behind this route of inquiry recognizes the frequent final common pathway of many patients in modern surgical intensive care units: infection and related organ dysfunction. The goal of prophylaxis or therapy is to provide the little push over the hump that so many patients cannot overcome, with the expectation that survival would then be enhanced and hospital discharge hastened.

The statistical crucifixion that befell previous major endotoxin antibody clinical trials is well known.1 Extraordinarily expensive treatments were found to favorably alter outcome in various subsets of inevitably

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();